314771-88-5 Usage
Description
4-QuinazolinaMine, N-(3-chloro-4-fluorophenyl)-6-nitro-7-[[(3S)-tetrahydro-3-furanyl]oxy]-, also known as (S)-N-(3-chloro-4-fluorophenyl)-6-nitro-7-(tetrahydrofuran-3-yloxy)quinazolin-4-amine, is a chemical compound that plays a crucial role in the synthesis of various pharmaceutical agents. It is characterized by its unique molecular structure, which includes a quinazoline core, a chloro-fluorophenyl group, a nitro group, and a tetrahydrofuranoxy group. 4-QuinazolinaMine, N-(3-chloro-4-fluorophenyl)-6-nitro-7-[[(3S)-tetrahydro-3-furanyl]oxy]is known for its potential applications in the development of therapeutic agents, particularly in the field of oncology and respiratory diseases.
Uses
Used in Pharmaceutical Synthesis:
4-QuinazolinaMine, N-(3-chloro-4-fluorophenyl)-6-nitro-7-[[(3S)-tetrahydro-3-furanyl]oxy]is used as a key intermediate in the synthetic preparation of 4-anilinoquinazolines with C-6 urea-linked side chains. These synthesized compounds serve as inhibitors of the epidermal growth factor receptor (EGFR), which is a common target for cancer therapies. By inhibiting EGFR, these agents can help control the growth and proliferation of cancer cells.
Used in Oncology:
In the field of oncology, 4-QuinazolinaMine, N-(3-chloro-4-fluorophenyl)-6-nitro-7-[[(3S)-tetrahydro-3-furanyl]oxy]is utilized in the preparation of (2Z)-Afatinib (A355305), a potent EGFR inhibitor. Afatinib is used for treating various types of cancer, including those of the respiratory tract, lungs, gastrointestinal tract, bile duct, and gallbladder. By targeting the EGFR pathway, Afatinib can help slow down or stop the growth of cancer cells, providing a valuable treatment option for patients with these conditions.
Used in Respiratory Disease Treatment:
4-QuinazolinaMine, N-(3-chloro-4-fluorophenyl)-6-nitro-7-[[(3S)-tetrahydro-3-furanyl]oxy]also plays a role in the development of treatments for respiratory diseases. 4-QuinazolinaMine, N-(3-chloro-4-fluorophenyl)-6-nitro-7-[[(3S)-tetrahydro-3-furanyl]oxy]is involved in the synthesis of (2Z)-Afatinib, which has been found to be effective in managing conditions such as asthma and chronic obstructive pulmonary disease (COPD). By targeting the EGFR pathway, Afatinib can help reduce inflammation and improve lung function in patients with these respiratory disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 314771-88-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,1,4,7,7 and 1 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 314771-88:
(8*3)+(7*1)+(6*4)+(5*7)+(4*7)+(3*1)+(2*8)+(1*8)=145
145 % 10 = 5
So 314771-88-5 is a valid CAS Registry Number.
314771-88-5Relevant articles and documents
Afatinib refined product synthetic method
-
, (2019/06/12)
The invention discloses an afatinib refined product synthetic method, and belongs to the technical field of organic synthesis. The method particularly comprises the following steps that 4-fluoro-2-aminobenzoic acid and formamidine acetate are subjected to a ring-closure reaction to synthesize a compound of the formula I; the compound of the formula I is subjected to a nitration reaction to synthesize a compound of the formul II; the compound of the formula II and 3-chloro-4-fluoroaniline are subjected to dehydration to synthesize a compound of the formula III, the compound of the formula III and 3-hydroxy-tetrahydrofuran synthesize a compound of a formula IV through a nucleophilic substitution reaction; the compound of the formula IV is reduced to generate a compound of the formula V underthe Pd/C catalysis; the compound of the formula V and crotonic acid synthesizes a compound of the formula VI through a dehydration condensation reaction; the compound of the formula VI and dimethylamine finally synthesize the compound of the formula VII, that is to say, an afatinib refined product is obtained. According to the afatinib refined product synthetic method, the reaction process condition is mild, the corrosion risk to reaction equipment is lowered, the reaction process is simplified, operation is easy, the purity of the product is high, and the yield is increased conveniently.
Arab league law for nepal intermediate high purity preparation method
-
, (2019/06/26)
The present invention relates to a high purity preparation method of Afatinib intermediate, and particularly relates to a high purity preparation method of an antineoplastic treatment medicine maleate Afatinib intermediate (II) compound, the method comprises the following steps: an objective product is obtained sequentially through substitution in two steps, reduction reaction and the like of 6-amino-7-fluoro-3,4-dihydro-quinazolin-4-one. The method is simple in process, economic and environmental-friendly, and suitable for industrial amplification requirements, and the manufactured finished product is high in purity.
4 - (Substituted phenylamino) aminoquin oxazolines, preparation method and application thereof
-
, (2018/01/11)
The invention specifically relates to novel 4-(substituted phenylamino)quinazoline compounds with antineoplastic activity and a preparation method thereof, belonging to the field of pharmaceutical chemical engineering. The 4-(substituted phenylamino)quinazoline compounds have an effective irreversible inhibiting effect on tyrosine kinase and/or good in-vivo pharmacokinetic behavior and are an effective tyrosine kinase irreversible inhibitor.
